AtriCure, Inc. $ATRC Stock Holdings Increased by Principal Financial Group Inc.

Principal Financial Group Inc. raised its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 45.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,296 shares of the medical device company’s stock after buying an additional 20,156 shares during the quarter. Principal Financial Group Inc.’s holdings in AtriCure were worth $1,834,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Diversify Wealth Management LLC increased its holdings in shares of AtriCure by 27.0% in the 1st quarter. Diversify Wealth Management LLC now owns 11,631 shares of the medical device company’s stock valued at $318,000 after acquiring an additional 2,476 shares during the last quarter. Valmark Advisers Inc. bought a new position in AtriCure during the first quarter worth $373,000. Fifth Third Bancorp bought a new position in AtriCure during the first quarter worth $51,000. Diversified Trust Co boosted its holdings in AtriCure by 7.1% in the first quarter. Diversified Trust Co now owns 40,090 shares of the medical device company’s stock worth $1,144,000 after purchasing an additional 2,654 shares during the period. Finally, Hsbc Holdings PLC boosted its holdings in AtriCure by 13.3% in the fourth quarter. Hsbc Holdings PLC now owns 17,224 shares of the medical device company’s stock worth $686,000 after purchasing an additional 2,028 shares during the period. Institutional investors own 99.11% of the company’s stock.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: UBS lowered its price target from $55 to $50 but maintained a Buy rating, implying substantial upside from recent trading levels. The revised target remains supportive of the long-term outlook for AtriCure’s medical-device business. UBS price target report
• Positive Sentiment: AtriCure recently exceeded quarterly expectations, reporting earnings per share of $0.18 versus an analyst estimate of $0.13 and revenue of $153.6 million versus estimates of $151.8 million. Results also improved from a loss in the year-ago period, supporting the company’s growth and profitability narrative. AtriCure earnings report
• Neutral Sentiment: Recent coverage is focused on whether options activity signals an unusually large upcoming move in ATRC. No specific direction is established, but elevated options interest may contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: Investors are also reviewing new share-registration filings. Such filings can provide AtriCure with financing flexibility, although the potential for future share issuance may raise dilution concerns. AtriCure share registration article
• Negative Sentiment: Several insiders sold shares: Director Sven Wehrwein reduced his holdings by about 38%, while executives Justin J. Noznesky and Vinayak Doraiswamy cut their positions by approximately 6% each. The sales, totaling roughly $1.42 million, may weigh on sentiment, particularly after ATRC’s strong recent run.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research note on Tuesday, July 21st. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday. UBS Group lowered their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Canaccord Genuity Group raised their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

AtriCure Price Performance

Shares of ATRC opened at $40.15 on Friday. The company has a market cap of $2.04 billion, a P/E ratio of 191.20 and a beta of 1.24. The stock has a fifty day moving average price of $30.91 and a 200 day moving average price of $31.29. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.18. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $43.18.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Insider Activity

In related news, Director Sven Wehrwein sold 25,000 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the sale, the director owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This trade represents a 38.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Karen Prange sold 3,000 shares of AtriCure stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total transaction of $85,950.00. Following the completion of the sale, the director owned 26,373 shares in the company, valued at approximately $755,586.45. This represents a 10.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 40,182 shares of company stock worth $1,505,092 in the last 90 days. 4.00% of the stock is currently owned by insiders.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.